Medical Oncologist
HER2-positive breast cancer
Trastuzumab biosimilars in India: cost and equivalence
Trastuzumab biosimilars are highly similar versions of the original antibody, approved after testing shows comparable effect and safety. In India they have made a year of HER2 treatment affordable for many more women. This page explains, in general terms, how they compare and what shapes the cost.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- What is a trastuzumab biosimilar, and does it work as well?
- The original and biosimilars, in general terms
- What shapes the cost of a year of treatment
- Steps that help make the year affordable
- The vocabulary, in plain language
- What to know about biosimilars honestly
- Discussing cost openly with your team
- How a biosimilar earns approval
- What people assume about biosimilars
- Common questions about biosimilars and cost
The short answer
What is a trastuzumab biosimilar, and does it work as well?
A biosimilar is a highly similar version of an antibody medicine, made after the original's patent protection ends. Trastuzumab biosimilars are approved only after testing shows they match the original closely in structure, how they act in the body, effectiveness and safety. In India, several biosimilars are available, and they have made a full year of HER2-targeted treatment affordable for many more women than before.
Why biosimilars are not exact copies
Antibodies are large proteins made in living cells, so no two batches are ever perfectly identical, even of the original. Biosimilars must show that any small differences make no meaningful difference to how well they work or how safe they are.
Why they cost less
Biosimilar makers do not repeat all the original research, and competition between products lowers prices. The savings over a full year can be substantial.
When the choice deserves more discussion
Switching between products partway through treatment, choosing a product with limited approval history, or deciding between an injection and a drip are worth talking through with your oncologist.
This page gives general information only. The choice of product is a decision for your oncologist.Side by side
The original and biosimilars, in general terms
Original trastuzumab
Approved biosimilars
The first product, with the longest track record
Tested against the original before approval
Higher cost
Usually considerably lower cost
Drip or injection under the skin
Usually given as a drip
Same heart monitoring
Same heart monitoring
Same side effects expected
Same side effects expected
What affects the cost
What shapes the cost of a year of treatment
The drug is only part of the total. These are the main things that change what a year costs.
Your body weight
The drip dose is calculated from your weight, so the amount of drug needed for each dose, and its cost, varies from person to person.
The product chosen
The original and different biosimilars are priced differently. Prices also change over time as more products become available.
Ask for a current written estimate.Other drugs in the plan
Chemotherapy, pertuzumab or T-DM1 add to the total. The overall cost of the year depends on everything included.
Tests and visits
Heart scans, blood tests and day-care charges add up across the year, alongside travel and time off work.
Ask about
- Insurance coverage for the product
- Government scheme eligibility
- Patient support programmes
Planning ahead
Steps that help make the year affordable
Ask for a written estimate early
Request the expected cost of the whole year, not just the first dose, including tests and day-care charges.
Check your insurance
Ask your insurer which products and settings are covered, and whether day-care treatment needs pre-authorisation.
Explore government schemes
Central and state health schemes may cover HER2 treatment. Ask the hospital's financial counsellor about eligibility.
Ask about support programmes
Some manufacturers and charities run programmes that reduce the cost of treatment for eligible patients.
Raise concerns before missing doses
If cost becomes a problem partway through, tell your team straight away. Options may exist that keep treatment on track.
Words you will hear
The vocabulary, in plain language
- Biosimilar
- A highly similar version of an antibody medicine, approved after testing against the original.
- Reference product
- The original medicine a biosimilar is compared with.
- Generic
- An exact chemical copy of a small-molecule drug. Antibodies cannot be copied exactly, which is why the term biosimilar is used.
- Interchangeability
- Whether one product can be switched for another during treatment.
- Pharmacovigilance
- Ongoing monitoring of a medicine's safety after approval.
- Weight-based dosing
- Calculating each drip dose from body weight.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
What to know about biosimilars honestly
Approved trastuzumab biosimilars are a genuine advance for access to treatment in India. The evidence supporting approved products is reassuring, and many women have completed treatment on them.
Not all products have the same history
Some biosimilars have been studied more extensively or used more widely than others. It is reasonable to ask your oncologist which product they recommend and why.
Switching mid-treatment
Changing products during the year is sometimes necessary because of supply or cost. Discuss it with your team first rather than switching on your own.
Cost figures change
Prices vary between hospitals, products and over time, so any figure you hear from others may not match your own. A written estimate from your hospital is the most reliable guide.
What this page cannot tell you
It cannot tell you the current price of any product or which is best for you. Ask your oncology team and financial counsellor.
Talking about money
Discussing cost openly with your team
Many families feel awkward raising money with doctors, worrying it might affect their care. Oncology teams in India discuss costs every day, and an honest conversation early helps them plan treatment you can actually complete.
Be clear about your limits
If there is a firm budget, say so. Your oncologist can then explain which parts of the plan matter most and where there is flexibility in product choice.
Involve the right people
Ask to meet the hospital's financial counsellor or social worker. They often know about schemes and support programmes that doctors may not mention.
Keep records
Keep bills, prescriptions and reports together. They are needed for insurance claims, scheme applications and tax benefits.
Behind the approval
How a biosimilar earns approval
Knowing what a biosimilar has to prove can make the choice feel less like a gamble. Regulators in India and abroad require a series of comparisons before a product can be sold.
Laboratory comparison
The biosimilar's structure is compared in detail with the original, including how the protein is shaped and how it binds to HER2. Only products that match closely move forward.
Studies in people
Studies then check that the biosimilar behaves in the body the same way and, usually, that women with HER2-positive breast cancer respond to it as they would to the original.
Watching after approval
Once in use, safety reports continue to be collected. This ongoing monitoring helps pick up any rare problem that studies could not show.
What this means for you
An approved biosimilar has cleared every one of these steps. Your oncologist can tell you which product they trust and the experience behind that choice.
Commonly believed
What people assume about biosimilars
A cheaper biosimilar must be a weaker medicine.
Approved biosimilars are tested to show they work comparably to the original. The lower price reflects reduced development costs and competition, not a weaker effect.
Biosimilars are the same as generic tablets.
Generics are exact chemical copies of simple drugs. Biosimilars are highly similar versions of complex proteins, which is why they need more testing before approval.
Biosimilars have fewer side effects because they are different.
They are expected to have the same side effects as the original, including the need for heart monitoring.
If I cannot afford the full year, there is no point starting.
Talk to your team first. Biosimilars, insurance, schemes and support programmes may make the full course possible.
Questions we are asked
Common questions about biosimilars and cost
Is a biosimilar safe for my whole treatment?
Approved biosimilars are tested for safety and effectiveness, and many women complete a full year on them. Your oncologist can explain the evidence behind the product they recommend.
Can I switch from the original to a biosimilar?
Sometimes. Discuss it with your oncologist, who will consider the products involved and where you are in treatment.
Does insurance cover biosimilars?
Many policies do. Coverage depends on your policy and the treatment setting. Ask your insurer and the hospital insurance desk before starting.
Why does my dose cost differ from someone else's?
Drip doses depend on body weight, and products and hospitals are priced differently. Comparing costs with others is rarely accurate.
Is there a biosimilar injection under the skin?
Most biosimilars are given as a drip. Ask your team what forms are currently available.
Do I still need heart scans?
Yes. Heart monitoring is the same whichever trastuzumab product you receive.
Who can help with the cost?
The hospital's financial counsellor or social worker can advise on insurance, government schemes and support programmes.
Where can I read about my own product?
Your oncology team will give you written information about the product planned for you. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Central Drugs Standard Control Organisation — Guidelines on similar biologics
- European Medicines Agency — Biosimilar medicines: overview
- Cancer Research UK — Trastuzumab (Herceptin)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.